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Solid organ transplant recipients (SOTR) suffer an
overall 2-fold increased risk of any malignancy
compared with the general population. Multiple
strategies exist to address this risk in these patients.
Revision of immunosuppression is the cornerstone
to reducing the risk of skin cancer development.
Here we present a patient with a remarkable clinical
response to immunosuppression revision.Case report
A 61-year-old man with a history of a kidney
transplantation in 2004 secondary to polycystic kid-
ney disease and a kidneyeliver transplant in 2008 for
decompensated cryptogenic cirrhosis maintained on
tacrolimus, prednisone, and mycophenolate pre-
sented to our office with an undifferentiated tumor
of the left parotid with distant metastases to the skin.
The patient’s medical history included multiple
cutaneous squamous cell and basal cell carcinomas
and a family history of polycystic kidney disease in
his father and sister.
Five months prior, he presented to his outside
dermatologist with several nodules on the left side of
the face. A parotid fine-needle aspiration found
atypical cells suspicious for a neoplasm without
obvious lineage differentiation. Left superficial pa-
rotidectomy found a high-grade malignant tumor
with areas of necrosis. The margins were positive,
and periparotid lymph nodes were involved.
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staining for a broad panel of epithelial, melanocytic,
and hematopoietic markers (Fig 1, A and B). The
final pathologic diagnosis was pleomorphic undif-
ferentiated epithelioid cell neoplasm.
Postoperative positron emission tomography
(PET) scan suggested persistent periparotid and
cervical lymph node activity, splenomegaly, and
distant metastases to the skin with increased uptake
in the left parietal scalp and left anterior chest wall.
Core biopsy from the left chest lesion and left scalp
found a high-grade undifferentiated epithelioid cell
neoplasm identical to the parotid tumor, confirming
distant cutaneous metastatic disease (Fig 1, C and
D). These metastases were completely excised, and
he underwent a modified neck dissection, which
found involvement of multiple cervical lymph
nodes.
At the time of presentation to our transplant
dermatology clinic, the patient had not undergone
treatment. In coordination with the transplant team,
recommendations were made to switch from myco-
phenolate to the mammalian target of rapamycin
(mTOR) inhibitor sirolimus while continuing onJAAD Case Reports 2015;1:S8-11.
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Fig 1. A, Low-power image of tumor nodules (lower portion of Fig 1, A) in parotid gland
(upper portion of figure), partially surrounded by a fibrous capsule. B, Higher magnification
shows sheets of pleomorphic undifferentiated epithelioid cells with numerous mitoses. Per
report of an outside facility that originally prepared the slides and read the pathology, a panel
of immunostains were performed including AE/AE3, EMA, CK5/6, CK7, p40, CK18, 34BE12,
p63, calponin, SMA, MITF, MART-1 and HMB-45, GFAP, LCA, CD3, CD20, CD138, CD34, ERG,
TTF-1, desmin were negative. Tumor was strongly vimentin positive and focally positive for
S100. C, Lower power image of needle biopsy from the chest wall shows sheets of pleomorphic
cells, focal necrosis, and hemorrhage. D, High-power view of undifferentiated pleomorphic
epithelioid cells and bizarre mitotic figures, histologically identical to the tumor in the parotid
gland. (Hematoxylin-eosin stain; original magnifications: A and C, 34; B and D, 340.)
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this time found progression of disease with increase
in size of the left parotid bed avid nodule from
0.93 0.6 cm to 1.33 0.8 cm and involvement of new
left cervical and left parathyroid lymph nodes (Fig 2).
Given the aggressive features of this tumor, the
calcineurin inhibitor, tacrolimus, was tapered off.
Without any other intervention or change in immu-
nosuppression, repeat PET scan 1 month after
discontinuing tacrolimus and 3 months after starting
sirolimus found significant improvement with reso-
lution of most periparotid and cervical nodes. Repeat
PET scan 4 months off calcineurin inhibitor and 6
months on sirolimus found no evidence of disease
(Fig 2). The patient’s graft functions remained stable,
and his only side effects included nonhealing ulcers
of the shin and mild proteinuria.DISCUSSION
Here we describe a SOTR with an aggressive
undifferentiated epithelioid tumor in the parotid
gland with skin metastases who had no evidence of
disease after converting to an mTOR inhibitor and
discontinuing his calcineurin inhibitor and myco-
phenolate without any other systemic therapy. To
date, the benefits of revising immunosuppression
regimens have been best studied in the treatment of
SOTRs with cutaneous squamous cell carcinoma
(SCC); however, there is supporting evidence that
decreasing immunosuppression and changing to an
mTOR inhibitor may be important in the prevention
and treatment of other tumors, including those that
are high grade and metastatic as in this case.
SOTRs suffer an overall 2-fold increased risk of
any malignancy when compared with the general
Fig 2. PET scan consolidations show progression of high-grade undifferentiated tumor of the
left parotid with metastasis to scalp and left subcutaneous breast between June and October
2013. No evidence of disease on PET scan 6 months after starting mTOR inhibitor sirolimus and
4 months after discontinuing calcineurin inhibitor tacrolimus.
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with an approximately 100-fold increased relative
risk. However, there is at least a 5-fold increased
relative risk of basal cell carcinoma, Kaposi’s sar-
coma, Non-Hodgkin’s lymphoma, liver cancer, anal
and vulvar cancer, and SCC of the lip compared with
normal population. Other poorly differentiated tu-
mors, such as undifferentiated pleomorphic sar-
coma, have been reported to be more common
and show a higher risk of metastases and mortality in
SOTRs.1
Revision of immunosuppression regimen in
SOTRs to manage SCC is recommended in patients
with SCC at high risk of metastasis, patients with life-
threatening cancer, or those with rapid development
of SCC (more than 5e10 per year). Early minimiza-
tion of immunosuppression or stopping immuno-
suppressive therapy altogether will significantly
reduce the development of new SCC at 5 years in
SOTRs and has been shown to improve outcomes for
patients with aggressive SCC.2 In a case series
examining cutaneous undifferentiated pleomorphic
sarcoma in SOTRs at several institutions, decreasing
immunosuppression was also noted to improve
outcomes.1
Conversion to an mTOR inhibitor such as
sirolimus may provide an additional antitumor
effect in high-risk transplant patients.3 Mammalian
target of rapamycin is part of the family of
phosphatidylinositol-3 kinase (PI3K)-related kinases
that is phosphorylated via PI3K/AKT signaling
pathway and activates downstream of cellular
growth signaling.4 In SOTRs, conversion to
sirolimus-based immunosuppression decelerated
the incidence of new SCC and induced regression
of existing skin lesions.5 A trial involving 120 SOTRs
and another with 830 patients receiving sirolimus or
continued on calcineurin inhibitors found signifi-
cantly longer duration of survival free of SCC after 2
years in the sirolimus group, and these patients
experienced up to half the number of new SCCscompared with those on calcineurin inhibitors with
no difference in graft function.6,7 A significant
decrease in all malignancies was noted in 5 random-
ized trials comparing sirolimus therapy with other
modes of immunosuppression in SOTRs. There was
a similar trend that did not reach statistical signifi-
cance in a recent large, randomized multicenter
study.6,8
The effectiveness of mTOR inhibitor immuno-
therapy in preventing and treating SCC and other
malignancies in transplant patient may not be
surprising given mTOR activates cellular growth.
Aberration of the mTOR/PI3K/AKT pathway is
suspected in many malignancies including cuta-
neous SCC, which is found to express significant
phospho-mTOR immunoreactivity.9,10 Use of
mTOR inhibitors show promising results in treat-
ment of advanced renal cell carcinoma, breast
carcinoma, mantle cell lymphoma, endometrial
cancer, glioblastoma, neuroendocrine tumors, and
soft tissue sarcomas.4 Side effects of mTOR in-
hibitors are not trivial and should be taken
into consideration when initiating therapy in a
patient. Common adverse events include periph-
eral edema, increased triglyceride and cholesterol
levels, hypertension, constipation or diarrhea,
nausea and abdominal pain, and anemia/
thrombocytopenia.
This case provides a successful example of
applying lessons learned from managing SCCs in
SOTRs with the addition of sirolimus therapy and
reduction of overall immunosuppression, coupled
with surgical excision, to eradicate an undifferenti-
ated metastatic malignancy.
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